Biotech and Pharmaceuticals Life Sciences

  • SAN JUAN, Puerto Rico— A Pennsylvania drug company announced Monday that it has launched a clinical trial of an experimental Zika vaccine in Puerto Rico, the part of the U.S. hardest hit by the mosquito-borne virus. Inovio Pharmaceuticals Inc. will be testing its DNA-based vaccine candidate on 160 adult volunteers in Puerto Rico. "The rapid progression of the...

  • CHICAGO/ TAMPA, Fla., Aug 26- The U.S. Food and Drug Administration recommended on Friday that all blood donated in the United States and its territories be tested for Zika virus, as it moves to prevent transmission of the virus through the blood supply. The agency said its decision to expand blood screening in the United States was based on concerns about more cases...

  • CHICAGO, Aug 26- The U.S. Food and Drug Administration recommended on Friday that all blood donated in the United States and its territories be tested for Zika virus, as it moves to prevent transmission of the virus through the blood supply. The agency said its move to expand blood screening in the United States was based on concerns about increasing cases of local...

  • BEIJING _ Sinovac Biotech Ltd. on Tuesday reported a second-quarter loss of $9.6 million, after reporting a profit in the same period a year earlier. On a per-share basis, the Beijing- based company said it had a loss of 17 cents. This story was generated by Automated Insights using data from Zacks Investment Research.

  • NASSAU, Bahamas _ Nymox Pharmaceutical Corp. on Monday reported a loss of $3.8 million in its second quarter. The Nassau, Bahamas- based company said it had a loss of 8 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • Executive Edge: Science behind earworms

    David Poeppel, New York University professor, explains why some songs are likely to stick in you mind than others.

  • MORRIS PLAINS, N.J. _ Immunomedics Inc. on Wednesday reported a loss of $15.9 million in its fiscal fourth quarter. The Morris Plains, New Jersey- based company said it had a loss of 17 cents per share. For the year, the company reported that its loss widened to $59 million, or 62 cents per share.

  • SAN DIEGO _ Adamis Pharmaceuticals Corp. on Monday reported a loss of $5.7 million in its second quarter. The San Diego- based company said it had a loss of 37 cents per share. Keywords: Adamis Pharmaceuticals, Earnings Report.

  • Aug 8- Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial. Treatment with the Australian company's mesenchymal precursor cell product,...

  • Shares of Bristol-Myers fell almost 16 percent to $63.54 on Friday after the company announced failure of the late-stage trial. Shares of Merck gained 8.7 percent to $62.89. "This is the worst-case scenario" for Opdivo and Bristol-Myers, Leerink analyst Seamus Fernandez said in a research note.

  • Health care and life sciences lead Merck's lifted full-year guidance

    Marcus Kuhnert, the chief financial officer of Merck, comments on the company's earnings report and explains which areas of the business are doing well.

  • U.S. concerns over Zika, which is spreading rapidly in the Americas and has hit Brazil the hardest, have risen since Florida authorities last week reported the first signs of local transmission in the continental United States in a Miami neighborhood. The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health federal...

  • WASHINGTON, Aug 3- U.S. government researchers said on Wednesday they have begun their first clinical trial of a Zika vaccine as concerns over the mosquito-borne virus mount following the first cases of local transmission in the continental United States. The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health...

  • HIV virus in an image taken with transmission electron microscopy.

    A judge ruled that an HIV pill to prevent infection could be funded by the U.K.'s state health service, in a victory for AIDS campaigners.

  • Training to be a Olympic champion

    How does World Olympic champion, Greg Rutherford get ready for important sports events and what did his DNA results show? CNBC takes a look.

  • Is DNA analysis worth it?

    Should sporting professionals, academics or even the average individual get their genetic data analyzed? CNBC investigates.

  • The Athlome Project: Setting its sights on a world record

    The Athlome project is an international joint effort to identify performance genes and genes that may influence the injury and predisposition to injury and illness.

  • Why this Olympic champion got his DNA analyzed

    World Olympic champion, Greg Rutherford explains to CNBC why he had his DNA analyzed, and what it might mean for his training and lifestyle choices.

  • How does genetic testing really work?

    At DNAFit, a genetic testing company, CNBC’s Louisa Bojesen takes a look at the step-by-step process of scientists analyzing and processing genetic data.

  • Greg Rutherford: Only the second UK man to win Olympic long jump gold

    Meet Greg Rutherford: World Olympic champion in long jump, who has managed to jump a record 8.51 meters – the length of almost two cars.